A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954

NCT07812077 ↗

Phase 1 Not yet recruiting 16 enrolled AstraZeneca Quotient Sciences · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabelled with a small amount of carbon-14 so it can be tracked in the body. This two-part study will take place at one site in Nottingham, United Kingdom, and will enroll 8 healthy men in each part, aged 30-65 years.

Timeline

Start: 2026-10-19
Primary completion: 2026-12-17
Completion: 2026-12-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD4954	Unknown	—	Oral
Subject	AZD4954	Unknown	—	Intravenous

Indications

No indication recorded.